Skip to content
Business Company News, Women

Women’s health focussed med-tech HeraMED Limited Announces Record Number of Active Users on HeraCARE Platform

Jane Morgan Management 3 mins read

SYDNEY, Australia – 19 June 2024 – HeraMED Limited (ASX: HMD) (‘HeraMED’ or the ‘Company’), a leading medical data and technology company transforming maternity care, is thrilled to announce a significant milestone for its innovative HeraCARE platform. As of 15 June 2024, the platform has reached a record number of accumulated users, totaling 3,533 registered mums, reflecting a 12% sequential growth since 31 March 2024.

The number of active users also saw a notable increase, with 560 active mums currently using the platform, surpassing the previous record of 517 active users as of 21 July 2022. This growth is largely driven by partnerships with US-based channel partner e-Lovu Health, which has 345 active users, and Perth-based private clinics Simply Women and JOGG, which collectively have 153 active users.

HeraCARE, a HIPAA-compliant, cloud-based remote maternity care platform, is designed to enhance provider and patient assurance, convenience, and empowerment. The platform's continuous growth is expected as HeraMED implements previously announced agreements and partnerships throughout 2024.

Key Highlights:

  • HeraCARE has achieved 3,533 accumulated users, a 12% increase since the end of March 2024.

  • The number of active mums on the platform reached 560, setting a new record.

  • US-based e-Lovu Health and Perth-based clinics Simply Women and JOGG are significant contributors to this growth.

  • HeraCARE offers remote pregnancy monitoring, customized care plans for low-risk pregnancies, and high-risk care for conditions such as hypertension, gestational diabetes, and maternal mental health, including post-partum care.

  • The accumulated data from HeraCARE is expected to provide early clinical intervention opportunities and drive HeraMED’s “data as an asset” strategy, integrating proprietary AI tools for enhanced analysis.

HeraMED’s Managing Director and CEO, Anoushka Gungadin, stated, “We continue to execute on our recently announced four-point strategic plan. The strong operating momentum and feedback from customers and health providers are translating into rapid accumulated user growth on our HeraCARE platform. In driving our data-as-an-asset strategy, we are building quality as well as quantity of data – high-quality data ensures accurate diagnosis and treatment, while sufficient quantity provides a comprehensive view of the patient's health, enabling more informed decision-making. We look forward to continuing to respond to the needs of mums and health providers as we commercialize HeraCARE and redefine how care is experienced and delivered.”

The HeraCARE platform not only delivers significant improvements in maternal health outcomes but also offers considerable cost savings. In the US alone, hypertensive disorders in mothers cost $7.5 billion annually, gestational diabetes costs $4.8 billion, and maternal mental health issues cost $18.1 billion annually.

As deployment at additional sites continues, the number of active users on HeraCARE is expected to rise, providing substantial opportunities for revenue growth, product development, and patient care innovations.


Key Facts:

● HeraMED continues to build momentum on its innovative HeraCARE platform with a record number of active and accumulated users (‘mums’);
● As at 15 June 2024, the number of accumulated mums on the HeraCARE platform reached 3,553 registered mums (+365 accumulated users or 12% sequential growth since 31 March 2024), including 560 active mums (previously record was 517 active users as at 21 July 2022);
● Recent growth can be primarily attributed to US based channel partner e-Lovu Health (345 active users) as well as Perth based private clinics Simply Women and JOGG (153 active users);
● HeraCARE is a HIPAA compliant1 , cloud-based, remote maternity care platform designed to drive provider and patient assurance, convenience, and empowerment;
● The number of accumulated mums on the HeraCARE platform is expected to continue growing as a number of previously announced agreements and partnerships2 are implemented; and
● Over time, accumulated HeraCARE platform data is expected to provide early clinical intervention opportunities, accelerating HeraMED’s “data as an asset” approach and the use/integration of proprietary AI tools and analysis.


About us:

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.


Contact details:

Jane Morgan 
jm@janemorganmanagement.com.au

Media

More from this category

  • Books Literature, Women
  • 24/07/2024
  • 11:15
Lovehoney AU

RE: Perth residents embrace #Smuttok: Sex expert reveals how erotic books can transform your self-pleasure and sex life

Hey, I hope you’re having a great day. Recently, I sent you an email with a press release revealing Perth residents love #SmutTok and…

  • Contains:
  • Biotechnology, Business Company News
  • 24/07/2024
  • 10:53
Jane Morgan Management

LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN

Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company"), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction ("ED") called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement to sophisticated and new institutional investors. The placement received demand significantly above the A$10.5 million raised. Key Highlights: Successful Fundraising: LTR Pharma has raised A$10.5 million through a private placement at an issue price of A$0.73 per share, representing a 13.2% discount to the 30-day…

  • Contains:
  • Business Company News, Oil Mining Resources
  • 24/07/2024
  • 10:36
Jane Morgan Management

C29 Metals Ltd (ASX:C29) Lodges Two New License Applications Around Ulytau Uranium Project

Perth, Australia – 24 July 2024 | C29 Metals Limited (ASX: C29) ("C29" or the "Company") is pleased to announce the lodging of two new licence applications around its high-grade Ulytau Uranium Project in Kazakhstan. The new applications, covering approximately 252km², significantly expand the project’s prospective footprint and reinforce C29’s strategic growth plans in the region. Key Highlights: New Licence Applications: C29 has lodged two new licence applications with the Kazakhstan Ministry of Natural Resources, covering a combined area of approximately 252km². These applications are interpreted to be within the same mineralised trend that hosts the high-grade Ulytau Uranium Project.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.